Dicerna Pharmaceuticals, Inc. (DRNA)
DRNAPrice: $38.22
Fair Value: 🔒
🔒score
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, ... more
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, a... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Douglas Fambrough |
| IPO Date | 2014-01-30 | CAGR | 0.4% |
| Employees | 302 | Website | dicerna.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
DRNA chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.47B | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 20.68 |
| P/CF Ratio | 16.27 | P/FCF Ratio | — |
| EPS | — | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 47.86% | Gross Margin | 1% |
| Operating Margin | -0.69% | Profit Margin | -0.69% |
| ROE | -0.78% | ROA | -0.16% |
| ROCE | -0.21% | Current Ratio | 3.48 |
| Quick Ratio | 3.48 | Cash Ratio | 0.71 |
| Debt/Equity | 0.38 | Interest Coverage | -5660.4 |
| Altman Z Score | — | Piotroski Score | — |